KRAS mutations have been implicated in the pathogenesis of different cancers, particularly common in colorectal cancer, lung cancer, melanoma, and pancreatic cancer (1,2). Analysis of KRAS mutations, particularly in codons 12, 13 and 61, has been shown to be incredibly valuable in optimizing the anti-EGFR therapies for different type of cancers like metastatic colorectal cancers (3-5).
Trimgen’s MutectorTM reagents
Based on Shifted Termination Assay (STA) technology, the kit uses special chemistry and a modified enzyme mixture to enrich the mutation signal and detect low level mutations in the sample. The STA technology has been widely used to detect BRAF, KRAS and other mutations in clinical samples including FFPE samples (see STA/Mutector-related Publications).
The difference:
- Detect more mutations - 17 mutations including the rare mutations (see below)
- Use of small clinical samples - such as fine needle aspiration (FNA)
- Simultaneously detect all possible mutations in target codon
- Sequencing-like accuracy and PCR-like sensitivity
Assay Information
Target Mutations Codon 12: G12A, G12C, G12D, G12R, G12S, G12V
Codon 13: G13A, G13C, G13D, G13R, G13S, G13V
Codon 61: Q61E, Q61H (CAT), Q61H*(CAC), Q61L, Q61R
Assay Platform Capillary sequencer ABI 3100, 3700, 3130, 3500
Assay Sensitivity Detects 1-2% KRAS mutations
Sample required 20-160 ng DNA
Assay Workflow
Order Information
| Cat. No. | Product Name | Target Mutations | Size | Documents |
| GP05-C3 | KRAS mutation detection kit | 12 KRAS mutations in codon 12 & 13 | 32 rxn | Manual, Product flyer |
| GP06 | KRAS codon 61 detection kit | 5 KRAS mutations in codon 61 | 32 rxn | Manual, Product flyer |
For research use only. Not for use in diagnostic procedures.
Data
Simultaneously detect all mutations of codon 12 in one tube:
Test results from FFPE samples:
Simultaneously detect all mutations of codon 13 in one tube:
Test results from FFPE samples:
Simultaneously detect 5 mutations of codon 61 (kit controls) in one tube:
Test result from FFPE samples:
Related Products
- FFPE Sample DNA Extraction– high yield DNA in 1 hour, 99% PCR success rate
- Mutation Analysis Reagents for Oncology – single platform for any somatic mutation
- Mutation Analysis Reagents for Pharmacogenetics – single platform for any genotyping
References
- Schubbert S et al. (2007). Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 4:295.
- Fernández-Medarde A et al. (2011). Ras in cancer and developmental diseases. Genes Cancer. 2:344.
- F Di Fiore, R et al. (2009). Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer. 103: 1765.
- De Roock W et al. (2011). KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12:594.
- Imamura Y et al. (2014). Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer. 13:135.